Assuming the critical role of the enhanced RAS activity in the development and maintenance of hypertension in Cyp1a1-Ren-2 transgenic rats [30–32,34–36,39,40], it seems plausible that the suppression of augmented intrarenal ANG II levels, both within the early and the late treatment protocols, is the main factor in antihypertensive actions of 20-HETE antagonist in our study. The gene discussed is CYP1A1; the disease is Hypertension.